Investigating the factors that impact on cancer occurrence within the cohort of diabetic patients, we found - apart from diabetes duration which had the strongest inverse influence - that insulin therapy, either as a monotherapy or in combination with metformin, increased the cancer risk by about 25%. Here, INS is linked to diabetes mellitus.